Acetylation is indispensable for p53 antiviral activity

Cell Cycle

Volumn 10, Issue 21, 2011, Pages 3701-3705

  Muñoz Fontela, Cesar ^a   González, Dolores ^c   Marcos Villar, Laura ^c   Campagna, Michela ^c   Gallego, Pedro ^c   González Santamaría, José ^c   Herranz, Daniel ^a,d   Gu, Wei ^b   Serrano, Manuel ^d   Aaronson, Stuart A ^a   Rivas, Carmen ^c  

^a Columbia University ^*  (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d Structural Biology and Biocomputing Programme   (Spain)

Author keywords

Acetylation; Antiviral activity; p53; Virus replication; VSV

Indexed keywords

LYSINE; PROTEIN P53;

ACETYLATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PROTEIN MODIFICATION; TRANSACTIVATION; VIRUS INFECTION; VIRUS REPLICATION;

VESICULAR STOMATITIS VIRUS;

EID: 80655129565     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.21.17899     Document Type: Article

References (34)

1. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126:121-34; PMID:16839881; DOI:10.1016/j. cell.2006.05.034.
2. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005; 102:8204-9; PMID:15928081; DOI:10.1073/pnas.0502857102.
3. Jacks T, Weinberg RA. Cell cycle control and its watchman. Nature 1996; 381:643-4; PMID:8649505; DOI:10.1038/381643a0.
4. Maiuri MC, Malik SA, Morselli E, Kepp O, Criollo A, Mouchel PL, et al. Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle 2009; 8:1571-6; PMID:19377293; DOI:10.4161/cc.8.10.8498.
5. Oren M. Relationship of p53 to the control of apoptotic cell death. Semin Cancer Biol 1994; 5:221-7; PMID:7948950.
6. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187:112-26; PMID:10341712; DOI:10.1002/(SICI)1096-9896(199901)187:1〈112: :AIDPATH250〉 3.0.CO;2-3.
7. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424:516-23; PMID:12872134; DOI:10.1038/nature01850.
8. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; PMID:11099028; DOI:10.1038/35042675.
9. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2:594-604; PMID:12154352; DOI:10.1038/nrc864.
10. Muñoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, Garcia-Sastre A, et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205:1929-38; PMID:18663127; DOI:10.1084/jem.20080383.
11. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell 2006; 21:307-15; PMID:16455486; DOI:10.1016/j.molcel.2006.01.020.
12. Kruse JP, Gu W. SnapShot: p53 posttranslational modifications. Cell 2008; 133:930-30.
13. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; DOI:10.1038/nrm2147.
14. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606; PMID:9288740; DOI:10.1016/S0092-8674(00)80521-8.
15. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 2004; 101:2259-64; PMID:14982997; DOI:10.1073/pnas.0308762101.
16. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008; 133:612-26; PMID:18485870; DOI:10.1016/j. cell.2008.03.025.
17. Allison SJ, Jiang M, Milner J. Oncogenic viral protein HPV E7 upregulates the SIRT1 longevity protein in human cervical cancer cells. Aging (Albany NY) 2009; 1:316-27; PMID:20157519.
18. Herzer K, Weyer S, Krammer PH, Galle PR, Hofmann TG. Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. Cancer Res 2005; 65:10830-7; PMID:16322229; DOI:10.1158/0008-5472.CAN-05-0880.
19. Liu Y, Colosimo AL, Yang XJ, Liao D. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol Cell Biol 2000; 20:5540-53; PMID:10891493; DOI:10.1128/MCB.20.15.5540-53.2000.
20. Nishimura T, Kohara M, Izumi K, Kasama Y, Hirata Y, Huang Y, et al. Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase. J Biol Chem 2009; 284:36442-52; PMID:19861417; DOI:10.1074/jbc.M109.043232.
21. Santos CR, Vega FM, Blanco S, Barcia R, Lazo PA. The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. Virology 2004; 328:254-65; PMID:15464845; DOI:10.1016/j. virol.2004.08.013.
22. Savelyeva I, Dobbelstein M. Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A. Oncogene 2011; 30:865-75; PMID:20935676; DOI:10.1038/onc.2010.461.
23. Brooks CL, Gu W. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 2009; 9:123-8; PMID:19132007; DOI:10.1038/nrc2562.
24. Jung-Hynes B, Ahmad N. Role of p53 in the anti-proliferative effects of SIRT1 inhibition in prostate cancer cells. Cell Cycle 2009; 8:1478-83; PMID:19377286; DOI:10.4161/cc.8.10.8408.
25. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107:137-48; PMID:11672522; DOI:10.1016/S0092-8674(01)00524-4.
26. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107:149-59; PMID:11672523; DOI:10.1016/S0092-8674(01)00527-X.
27. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. SIRT1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 2008; 105:9793-8; PMID:18599449; DOI:10.1073/pnas.0802917105.
28. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN. Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 1998; 273:33048-53; PMID:9830059; DOI:10.1074/jbc.273.49.33048.
29. Chelbi-Alix MK, Pelicano L, Quignon F, Koken MH, Venturini L, Stadler M, et al. Induction of the PML protein by interferons in normal and APL cells. Leukemia 1995; 9:2027-33; PMID:8609713.
30. Lavau C, Marchio A, Fagioli M, Jansen J, Falini B, Lebon P, et al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995; 11:871-6; PMID:7545807.
31. Stadler M, Chelbi-Alix MK, Koken MH, Venturini L, Lee C, Saib A, et al. Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. Oncogene 1995; 11:2565-73; PMID:8545113.
32. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406:207-10; PMID:10910364; DOI:10.1038/35021000.
33. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003; 100:10794-9; PMID:12960381; DOI:10.1073/pnas.1934713100.
34. Palmero I, Serrano M. Induction of senescence by oncogenic Ras. Methods Enzymol 2001; 333:247-56; PMID:11400340; DOI:10.1016/S0076-6879(01)33060-4.